Advertisement
Advertisement

Cefdinir


Generic Medicine Info
Indications and Dosage
Oral
Acute exacerbations of chronic bronchitis
Adult: 300 mg 12 hourly for 5-10 days or 600 mg 24 hourly for 10 days. Dosage and treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).
Child: ≥13 years Same as adult dose. Dosage and treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).

Oral
Pharyngitis, Tonsillitis
Adult: 300 mg 12 hourly for 5-10 days or 600 mg 24 hourly for 10 days. Dosage and treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).
Child: 6 months to 12 years As oral susp: 7 mg/kg 12 hourly for 5-10 days or 14 mg/kg 24 hourly for 10 days (Max: 600 mg/day); ≥13 years Same as adult dose. Dosage and treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).

Oral
Acute maxillary sinusitis
Adult: 300 mg 12 hourly or 600 mg 24 hourly for 10 days. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Child: 6 months to 12 years As oral susp: 7 mg/kg 12 hourly or 14 mg/kg 24 hourly for 10 days (Max: 600 mg/day); ≥13 years Same as adult dose. Dosage and treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).

Oral
Community-acquired pneumonia
Adult: 300 mg 12 hourly for 10 days. Dosage and treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).
Child: ≥13 years Same as adult dose. Dosage and treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).

Oral
Uncomplicated skin and skin structure infections
Adult: 300 mg 12 hourly for 10 days. Dosage and treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).
Child: 6 months to 12 years As oral susp: 7 mg/kg 12 hourly for 10 days (Max: 600 mg/day); ≥13 years Same as adult dose. Dosage and treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).

Oral
Acute otitis media
Child: 6 months to 12 years As oral susp: 7 mg/kg 12 hourly for 5-10 days or 14 mg/kg 24 hourly for 10 days (Max: 600 mg/day). Dosage and treatment recommendations may vary among countries and between individual products (refer to local or specific product guidelines).
What are the brands available for Cefdinir in Philippines?
Other Known Brands
  • Cefnaxl
  • Nirocef
  • Orcef-DS
  • Safdicure
  • Sefdy
Renal Impairment
Acute exacerbations of chronic bronchitis; Community-acquired pneumonia; Uncomplicated skin and skin structure infections; Pharyngitis; Tonsillitis; Acute maxillary sinusitis:
Patients on chronic haemodialysis: Initially, 300 mg every other day. Administer a supplemental dose (300 mg) after the completion of each dialysis session, then continue the subsequent doses every other day.
CrCl (mL/min) Dosage
<30 300 mg once daily.
Administration
Cefdinir May be taken with or without food.
Reconstitution
Powder for oral susp: Reconstitute with the appropriate volume of water as indicated on the label. Shake well until suspended and before each use.
Contraindications
Hypersensitivity to cefdinir or other cephalosporins.
Special Precautions
Patient with history of colitis and hypersensitivity to penicillin. Not indicated for the treatment of viral infections (e.g. common cold). Renal impairment (CrCl <30 mL/min or undergoing chronic haemodialysis). Children. Pregnancy and lactation.
Adverse Reactions
Significant: Bacterial or fungal superinfection (prolonged use), antibiotic-associated (non-Clostridioides difficile) diarrhoea; immediate and delayed hypersensitivity reactions (e.g. anaphylaxis, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis). Rarely, hypoprothrombinaemia.
Blood and lymphatic system disorders: Lymphocytosis.
Gastrointestinal disorders: Nausea, vomiting, abdominal pain.
General disorders and administration site conditions: Fever.
Investigations: Increased urinary protein.
Nervous system disorders: Headache, seizure.
Renal and urinary disorders: Microscopic haematuria.
Reproductive system and breast disorders: Vaginitis, vulvovaginal candidiasis.
Skin and subcutaneous tissue disorders: Rash.
Potentially Fatal: Clostridioides difficile-associated diarrhoea and colitis.
Monitoring Parameters
Perform culture and susceptibility tests; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks. Obtain hypersensitivity history from the patient prior to therapy. Monitor renal function. Assess for signs and symptoms of anaphylaxis during 1st dose; severe or bloody diarrhoea.
Drug Interactions
Decreased absorption with antacids or Fe supplements. Concomitant use with Fe-containing agents may cause reddish stools. Reduced renal excretion and increased serum concentration with probenecid.
Lab Interference
May result in a false-positive reaction for urinary ketones with nitroprusside-based tests. May cause false-positive results in urine glucose tests using Clinitest®, Benedict's solution, or Fehling's solution. May result in a positive direct Coomb's test.
Action
Description:
Mechanism of Action: Cefdinir, a 3rd generation cephalosporin, is a β-lactam antibiotic. It binds to 1 or more of the penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thereby preventing cell wall biosynthesis and causing eventual bacterial lysis.
Pharmacokinetics:
Absorption: Absorbed from the gastrointestinal tract. Bioavailability: 16-21% (cap); 25% (susp). Time to peak plasma concentration: 2-4 hours.
Distribution: Distributed into the blister fluid, middle ear fluid, tonsils, sinus, and lung tissues. Volume of distribution: 0.35 ± 0.29 L/kg. Plasma protein binding: 60-70%.
Metabolism: Minimally metabolised.
Excretion: Mainly via urine (approx 12-18% as unchanged drug). Elimination half-life: 1.7 ± 0.6 hours.
Chemical Structure

Chemical Structure Image
Cefdinir

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 6915944, Cefdinir. https://pubchem.ncbi.nlm.nih.gov/compound/Omnicef. Accessed July 31, 2024.

Storage
Store between 15-30°C. Reconstituted powder for oral susp: Store at room temperature (20-25°C) and use within 10 days. Storage and stability recommendations may vary among individual products and between countries (refer to specific product guidelines).
MIMS Class
Cephalosporins
ATC Classification
J01DD15 - cefdinir ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
References
Anon. Cefdinir. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 04/06/2024.

Brayfield A, Cadart C (eds). Cefdinir. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/06/2024.

Cefdinir Capsule (Aurobindo Pharma Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/06/2024.

Cefdinir Powder, for Suspension (Aurobindo Pharma Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/06/2024.

Cefdinir. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 04/06/2024.

Cefdinir. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 04/06/2024.

Trinir 125 mg/5 mL Powder for Suspension (AGB Pharmaceutical Trading and Consultancy Corp.). MIMS Philippines. http://www.mims.com/philippines. Accessed 04/06/2024.

Trinir 300 mg Capsule (AGB Pharmaceutical Trading and Consultancy Corp.). MIMS Philippines. http://www.mims.com/philippines. Accessed 04/06/2024.

Disclaimer: This information is independently developed by MIMS based on Cefdinir from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2025 MIMS. All rights reserved. Powered by MIMS.com
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement